H. Lee Moffitt Cancer Center and Research Institute: Carcinoma trials

The registry lists 12 Carcinoma studies with H. Lee Moffitt Cancer Center and Research Institute as lead sponsor. 0 are open to participants now and 6 have results posted.

Early Phase 1 1Phase 1 7Phase 2 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Cemiplimab-rwlc for Unresectable Locally Recurrent and/or Metastatic CSCCTerminatedNCT04242173Phase 2Results posted
• Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung CancerCompletedNCT03215810Phase 1Results posted
• FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine CarcinomasTerminatedNCT03042780Phase 2Results posted
• Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the BladderTerminatedNCT02901548Phase 2Results posted
• Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced CholangiocarcinomaCompletedNCT02631590Phase 2Results posted
• Enzalutamide in Combination With Gemcitabine and Cisplatin in Bladder CancerCompletedNCT02300610Phase 1Results posted
• SELINEXOR in Combination w/Bevacizumab and Atezolizumab in Newly Diagnosed Advanced Hepatocellular CarcinomaTerminatedNCT05093608Phase 1
• Biological Outcomes of Pramlintide in Resectable Cutaneous Squamous Cell Carcinoma: A Pilot StudyWithdrawnNCT04252612Early Phase 1
• IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid TumorsCompletedNCT03758781Phase 1
• Sorafenib and Bavituximab Plus SBRT in Unresectable Hepatocellular CarcinomaWithdrawnNCT02989870Phase 1
• Stereotactic Body Radiotherapy and Concurrent Cisplatin for Re-Irradiation of Unresectable, Recurrent Squamous Cell Carcinomas of Head and NeckCompletedNCT02158234Phase 1
• Phase I Study of Percutaneous Valrubicin for Upper Tract Urothelial CarcinomaCompletedNCT01606345Phase 1